about
Multidisciplinary meeting on male breast cancer: summary and research recommendationsHigh risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerThe feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulatiThe MINDACT trial: the first prospective clinical validation of a genomic toolIndividualization of therapy using Mammaprint: from development to the MINDACT TrialClinical application of the 70-gene profile: the MINDACT trialClass III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxelESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).Time for more optimism in metastatic breast cancer?Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools.Comparison of prognostic gene expression signatures for breast cancerPhase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.ASCO 2009: What's New in Breast Cancer Therapy?Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.Resistance to trastuzumab: a necessary evil or a temporary challenge?Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer.Landmark adjuvant randomized clinical trials of systemic therapy in early breast cancer.Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.Use and abuse of taxanes in the management of metastatic breast cancer.Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?Challenges in breast cancer clinical trial design in the postgenomic era.Breast cancer gene expression profiling: clinical trial and practice implications.Bringing molecular prognosis and prediction to the clinic.Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patientsProliferative markers as prognostic and predictive tools in early breast cancer: where are we now?The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic reviewBreast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself.Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be tGene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.Current perspectives of epothilones in breast cancer.New tools for assessing breast cancer recurrence.
P50
Q24631800-4F563641-99EB-4C7E-B92C-2BEC96BF186CQ24641848-325CDF0F-90FB-4385-860B-8B45F4863D8EQ28216881-29BF2813-29F1-46D8-94D3-F834CFC91751Q28242008-ABC7E692-90D9-424D-B724-0E4356465F34Q28249470-3882C813-D66A-47DA-AA01-0929E0F33342Q28267891-1BE3E936-6FD8-44E2-AA7F-3539A7D4B71BQ28287239-492CDE6F-7186-49AD-9158-1B15FFF1185BQ30317064-0CB43A72-F613-4085-9B8D-C00793375B62Q30354522-7E5F1D74-295A-4218-8322-5AA76C228D49Q31050729-422029FA-5DB8-459D-8B4A-9DECD3CA0561Q33286957-1A7F60B1-AA17-4A75-90D0-D1455B6F57E4Q33362164-FCB1473E-4ED2-482C-8A6A-14CEB9858456Q33366766-8F8098BB-B760-498D-AAA6-FB299D60BBA5Q33377558-28A8B77A-4488-4C7D-AB55-9DC504A18F08Q33698446-D68D8E72-1F3D-414F-B15D-3EB294D0A178Q34019589-B4D15DD8-D8E4-4CF4-A46D-50B69CE4192BQ34138399-B2530FD5-F5FA-44D3-A52E-4633F132C2E1Q34433731-E8443CD3-65EA-42ED-9C4D-AEC313E7D1F4Q34563697-687E0831-85CF-45BB-A4BA-3B9D8E002C14Q34803601-F0BD2186-AA06-459F-B33D-FB473B7A47E2Q34993786-B36D3EF1-84AB-4A9F-B702-30DEF5AA1DEDQ35019658-718B3FAF-82D0-4636-8DF5-0203C13081DFQ35208044-6A15CAF6-AAE9-4B58-81D9-E1F20808AA4CQ35211298-CB010795-37A2-40F5-8738-F4EFFAC9BC77Q35212595-54E1F429-3208-454C-8656-5427E4BD1459Q35610564-A4243D03-C1D9-49F8-A688-1C0BA5A6D02AQ35820247-13A9B8FE-97A7-4A28-9474-03136FC6B84CQ35997214-70332D3D-76EB-4592-92B0-563A6E6D9360Q36050579-EB0290C1-3229-4FEE-AB17-C1EA3B7732AAQ36130358-CD54C823-DA99-453F-BE08-7B7ACC09455BQ36171157-3A8BCE2E-B29F-4D60-A861-D715F493B48DQ36175746-8141571E-137C-4D1A-B9E2-73297D3E3338Q36294151-020C3637-379F-4A37-A87A-27524487D21EQ36395909-166A1329-6616-4993-B9BB-5370177B017DQ36607542-23DF64C2-B4EF-4FBD-9223-48FC320823DFQ36610188-96C8B298-D377-48CA-B680-E175ABC5BDF9Q36613514-7874C0B6-0893-4FFA-B3F3-2E92E8660A3EQ36779175-147BAFCA-D4CB-4D47-AB8B-F75819D6E4E2Q37051869-35A685EC-C293-4315-9D47-0FC7B24BAA59Q37084365-14F2902C-C3D0-4CF0-B6B2-897A60D3AAF8
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Fatima Cardoso
@ast
Fatima Cardoso
@en
Fatima Cardoso
@es
Fatima Cardoso
@sl
type
label
Fatima Cardoso
@ast
Fatima Cardoso
@en
Fatima Cardoso
@es
Fatima Cardoso
@sl
prefLabel
Fatima Cardoso
@ast
Fatima Cardoso
@en
Fatima Cardoso
@es
Fatima Cardoso
@sl
P214
P227
P244
P106
P21
P214
P227
1057247782
P244
no2005090611
P31
P496
0000-0002-6692-2249
P569
1966-01-01T00:00:00Z
P734
P735
P7859
lccn-no2005090611